| Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors. | Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors.
Jacobsen F, Pushpadevan R, Viehweger F, Freytag M, Schlichter R, Gorbokon N, Büscheck F, Luebke AM, Putri D, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Fraune C, Bernreuther C, Lebok P, Sauter G, Minner S, Steurer S, Simon R, Burandt E, Dum D, Lutz F, Marx AH, Krech T, Clauditz TS. | 04/18/2024 |
| Molecular mechanism underlying the increased risk of colorectal cancer metastasis caused by single nucleotide polymorphisms in LI-cadherin gene. | Molecular mechanism underlying the increased risk of colorectal cancer metastasis caused by single nucleotide polymorphisms in LI-cadherin gene.
Yui A, Kuroda D, Maruno T, Nakakido M, Nagatoishi S, Uchiyama S, Tsumoto K., Free PMC Article | 05/5/2023 |
| The Relationship between Cadherin Polymorphisms and the Risk of Delayed Encephalopathy after Acute Carbon Monoxide Poisoning in the Chinese Han Population. | The Relationship between Cadherin Polymorphisms and the Risk of Delayed Encephalopathy after Acute Carbon Monoxide Poisoning in the Chinese Han Population.
Liu X, Zeng J, Zhang X, Gu J, Zhang F, Han Y, Zhang P, Li W, Gu R., Free PMC Article | 02/19/2022 |
| CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin. | CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin.
Ma H, Xiao W, Wang M, Shi X. | 01/22/2022 |
| Mechanism of dimerization and structural features of human LI-cadherin. | Mechanism of dimerization and structural features of human LI-cadherin.
Yui A, Caaveiro JMM, Kuroda D, Nakakido M, Nagatoishi S, Goda S, Maruno T, Uchiyama S, Tsumoto K., Free PMC Article | 12/11/2021 |
| A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. | A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
Lopes N, Bergsland C, Bruun J, Bjørnslett M, Vieira AF, Mesquita P, Pinto R, Gomes R, Cavadas B, Bennett E, Pereira L, Lothe RA, Almeida R, David L. | 06/26/2021 |
| Clinical correlation of cadherin-17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma. | Clinical correlation of cadherin-17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma.
Zheng BH, Shen S, Wong KF, Gong ZJ, Sun WT, Ni XJ, Wang JW, Hu MY, Liu H, Ni XL, Liu HB, Luk JM, Suo T. | 03/28/2021 |
| Combined use of LI-cadherin and CDX2 can improve the accuracy in the diagnosis of metastatic adenocarcinoma cells in serous cavity effusion and provide some bases of histologic origin because of their high sensitivity and specificity. | LI-cadherin and CDX2: Useful Markers in Metastatic Gastrointestinal Adenocarcinoma Cells in Serous Cavity Effusion.
Ma H, Yu J, Tang J. | 07/25/2020 |
| immunophenotyping with CLDN18, CDH17, and PAX8 might improve the diagnostic accuracy of histopathological classifications of endocervical adenocarcinoma | Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.
Asaka S, Nakajima T, Kugo K, Kashiwagi R, Yazaki N, Miyamoto T, Uehara T, Ota H. | 04/25/2020 |
| CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways. | Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death.
Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, Kaifi JT, Miao Y, Li M, Jiang K, Li G. | 04/11/2020 |
| CDH17 silencing induced apoptosis and inhibited autophagy in KM12SM and KM12C cells, and this autophagy protected the cells from apoptotic cell death. | Silencing of cadherin-17 enhances apoptosis and inhibits autophagy in colorectal cancer cells.
Tian X, Han Z, Zhu Q, Tan J, Liu W, Wang Y, Chen W, Zou Y, Cai Y, Huang S, Chen A, Zhan T, Huang M, Liu M, Huang X. | 03/16/2019 |
| Down-expression of CDH17 gene can significantly improve apoptosis-inducing effects of cisplatin in vitro and in vivo, which is a new strategy to improve chemotherapeutic effects on gastric cancer. | Downregulation of liver-intestine cadherin enhances cisplatin-induced apoptosis in human gastric cancer BGC823 cells.
Liu M, Han Z, Zhu QX, Tan J, Liu WJ, Wang YF, Chen W, Zou YL, Cai YS, Tian X, Huang X. | 01/12/2019 |
| CDH17 has a role in altering MMP-2 expression via canonical NF-kappaB signalling in human gastric cancer | CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer.
Jiang XJ, Lin J, Cai QH, Zhao JF, Zhang HJ. | 12/22/2018 |
| Data show that alteration in beta-catenin expression, a core component of the CDH17/beta-catenin axis, in tumors affects serine peptidase inhibitor Kazal type 1 (SPINK1) serum levels in hepatocellular carcinoma (HCC) patients. | Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH, Luo R, Lam BYH, Sung WK, Lam TW, Luk JM, Leung MS, Chan KT, Wang HK, Chan CM, Poon RT, Lee NP. | 07/7/2018 |
| However, CDH17 expression was significantly elevated in patients with stage II and III gastric cancers compared to that in healthy controls (p= 0.023 and p= 0.037, respectively). | Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer.
Choi B, Lee HJ, Min J, Choe HN, Choi YS, Son YG, Ahn HS, Suh YS, Goldenring JR, Yang HK. | 04/28/2018 |
| CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. | Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M., Free PMC Article | 02/10/2018 |
| CDH17 is a sensitive marker for midgut WDNETs, and the CDH17+/CDX2-/TTF1- phenotype was found to be sensitive (92%) and specific (91%) for hindgut well-differentiated neuroendocrine tumours (WDNETs). | Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
Snow AN, Mangray S, Lu S, Clubwala R, Li J, Resnick MB, Yakirevich E. | 04/22/2017 |
| Using a lentiviral system as a delivery mediator of RNA interference, we found that inhibition of CDH17 can lead to reduce proliferation and increase apoptosis of gastric cancer cell line MKN28 in vitro and significantly diminish their tumorigenicity in vivo. Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer. | Inhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cells.
Li R, Yang HQ, Xi HL, Feng S, Qin RH., Free PMC Article | 04/8/2017 |
| In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. | CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2.
Altree-Tacha D, Tyrrell J, Haas T. | 03/11/2017 |
| These data indicate that knockdown of LIcadherin facilitates the invasion of cancer cells by degrading extracellular matrix components via activation of MMP2 and 9, and increases cancer cell adhesion and migration via altered expression of galectin3. | Knockdown of LI-cadherin alters expression of matrix metalloproteinase-2 and -9 and galectin-3.
Yu Q, Shen W, Zhou H, Dong W, Gao D. | 02/18/2017 |
| Fascin-1 expression, cadherin-17 expression, tumor size, and differentiation were independent risk factors for GC. | Correlations of fascin-1 and cadherin-17 protein expression with clinicopathologic features and prognosis of patients with gastric cancer.
Tu L, Xu J, Wang M, Zhao WY, Zhang ZZ, Zhu CC, Tang DF, Zhang YQ, Wang DH, Zuo J, Cao H. | 02/4/2017 |
| Mutations in CDH17 gene is associated with idiopathic hypereosinophilic syndrome. | Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome.
Andersen CL, Nielsen HM, Kristensen LS, Søgaard A, Vikeså J, Jønson L, Nielsen FC, Hasselbalch H, Bjerrum OW, Punj V, Grønbæk K., Free PMC Article | 10/8/2016 |
| Review/Meta-analysis: data reflect the role of CDH17 in tumor proliferation and metastasis among gastric cancer patients. | Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.
Long ZW, Zhou ML, Fu JW, Chu XQ, Wang YN., Free PMC Article | 01/23/2016 |
| CDH17 is a sensitive (81%) and highly specific (100%) marker for metanephric adenoma. | Cadherin 17 is a sensitive and specific marker for metanephric adenoma.
Yakirevich E, Magi-Galluzzi C, Grada Z, Lu S, Resnick MB, Mangray S., Free PMC Article | 05/16/2015 |
| RGD motif present in cadherin 17 induces integrin activation and tumor growth | An RGD motif present in cadherin 17 induces integrin activation and tumor growth.
Bartolomé RA, Peláez-García A, Gomez I, Torres S, Fernandez-Aceñero MJ, Escudero-Paniagua B, Imbaud JI, Casal JI., Free PMC Article | 02/14/2015 |